Breast Cancer Research
IF
4.99
Papers
4748
Papers 4850
1 page of 485 pages (4,850 results)
Newest
#1Gerardo GattiH-Index: 9
#1Gerardo Gatti (CONICET: National Scientific and Technical Research Council)H-Index: 1
Last. Mariana MaccioniH-Index: 20
view all 14 authors...
BACKGROUND Characterization of breast cancer (BC) through the determination of conventional markers such as ER, PR, HER2, and Ki67 has been useful as a predictive and therapeutic tool. Also, assessment of tumor-infiltrating lymphocytes has been proposed as an important prognostic aspect to be considered in certain BC subtypes. However, there is still a need to identify additional biomarkers that could add precision in distinguishing therapeutic response of individual patients. To this end, we fo...
Source
#1Xuan Sun (University of Adelaide)H-Index: 3
#2Sarah M. Bernhardt (University of Adelaide)H-Index: 2
Last. Wendy V. Ingman (University of Adelaide)H-Index: 22
view all 10 authors...
BACKGROUND Transforming growth factor beta1 (TGFB1) is a multi-functional cytokine that regulates mammary gland development and cancer progression through endocrine, paracrine and autocrine mechanisms. TGFB1 also plays roles in tumour development and progression, and its increased expression is associated with an increased breast cancer risk. Macrophages are key target cells for TGFB1 action, also playing crucial roles in tumourigenesis. However, the precise role of TGFB-regulated macrophages in...
Source
#1Angela DeMichele (UPenn: University of Pennsylvania)H-Index: 56
#2Massimo Cristofanilli (NU: Northwestern University)H-Index: 78
Last. Richard S. Finn (UCLA: University of California, Los Angeles)H-Index: 64
view all 11 authors...
BACKGROUND Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on survival outcomes in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-negative (HER2-) metastatic breast cancer (MBC) treated in routine clinical practice in the USA. PATIENTS AND METHODS This was a retrospective observatio...
Source
#1Francesca GalardiH-Index: 11
#2Francesca De LucaH-Index: 8
Last. Luca MalorniH-Index: 19
view all 19 authors...
BACKGROUND Circulating tumor cells (CTCs) are prognostic in patients with advanced breast cancer (ABC). However, no data exist about their use in patients treated with palbociclib. We analyzed the prognostic role of CTC counts in patients enrolled in the cTREnd study, a pre-planned translational sub-study of TREnd (NCT02549430), that randomized patients with ABC to palbociclib alone or palbociclib plus the endocrine therapy received in the prior line of treatment. Moreover, we evaluated RB1 gene...
Source
#1Jonine D. Figueroa (NIH: National Institutes of Health)H-Index: 45
#2Gretchen L. Gierach (NIH: National Institutes of Health)H-Index: 25
Last. Thomas E. Rohan (Albert Einstein College of Medicine)H-Index: 79
view all 14 authors...
BACKGROUND Among women diagnosed with invasive breast cancer, 30% have a prior diagnosis of benign breast disease (BBD). Thus, it is important to identify factors among BBD patients that elevate invasive cancer risk. In the general population, risk factors differ in their associations by clinical pathologic features; however, whether women with BBD show etiologic heterogeneity in the types of breast cancers they develop remains unknown. METHODS Using a nested case-control study of BBD and breast...
Source
#2Simone Schrading (RWTH Aachen University)H-Index: 12
Last. Ulrike NitzH-Index: 19
view all 25 authors...
Background Prediction of histological tumor size by post-neoadjuvant therapy (NAT) ultrasound and magnetic resonance imaging (MRI) was evaluated in different breast cancer subtypes. Methods Imaging was performed after 12-week NAT in patients enrolled into three neoadjuvant WSG ADAPT subtrials. Imaging performance was analyzed for prediction of residual tumor measuring ≤10 mm and summarized using positive (PPV) and negative (NPV) predictive values. Results A total of 248 and 588 patients had MRI ...
Source
#1Iain R. Macpherson (Glas.: University of Glasgow)H-Index: 18
#2Yaohua He (Eisai)
Last. Carlo Palmieri (University of Liverpool)H-Index: 32
view all 3 authors...
BACKGROUND The recommended starting dose of eribulin in patients with hepatic impairment is based on the Child-Pugh score, largely informed by a pharmacokinetic study of 18 patients. In the pivotal studies of eribulin in metastatic breast cancer (Study 301 and Study 305 [EMBRACE]), entry criteria and dose modifications were based on liver-function test (LFT) results rather than Child-Pugh score. In populations such as patients with metastatic breast cancer, in which metastatic infiltration is th...
Source
#1Shih-Ying Wu (Wake Forest University)H-Index: 13
#2Sambad Sharma (Wake Forest University)H-Index: 10
Last. Kounosuke Watabe (Wake Forest University)H-Index: 47
view all 7 authors...
Source
#1Zoltan Szucs (University of Cambridge)H-Index: 1
#2James Joseph (University of Cambridge)H-Index: 16
Last. André A. Neves (University of Cambridge)H-Index: 21
view all 7 authors...
Source
#1Lauren Darrigues (PSL Research University)H-Index: 4
#2Jean-Yves Pierga (Curie Institute)H-Index: 48
Last. François-Clément Bidard (Curie Institute)H-Index: 42
view all 15 authors...
BACKGROUND Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard therapy in women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC). Palbociclib has been shown to increase the progression-free survival (PFS) overall but no predictive biomarker of palbociclib efficacy has been validated so far. We thus evaluated whether early changes of circu...
Source
12345678910
Top fields of study
Pathology
Oncology
Surgical oncology
Cancer research
Breast cancer
Medicine